Roche drops two Huntington’s programmes from Ionis
Why it matters: The decisions eliminate two of Roche’s three clinical approaches to lowering the toxic huntingtin protein…
OMass attracts $420m Roche wager on IBD programme
UK biotech OMass Therapeutics has revealed its first major pharma partnership, with Roche’s Genentech unit paying $20 million…